BIOTECH & MEDTECH

1. Leadership Challenges in Biotech & Medtech Transformation

1.1 Talent and leadership shortage

In Europe, VC-backed healthtech firms overwhelmingly rate Leadership and Management as the most vital yet most deficient skill set.
Over 70% of healthcare organizations report critical digital skills gaps—extending to leadership unable to handle digital transformation.
Executive-level roles blending scientific rigor with commercial insight are rare—often forcing traditional scientists into unfamiliar managerial positions.

1.2 Regulatory and compliance pressure

Europe’s evolving Medical Device Regulation (MDR) and UKCA marking post-Brexit are heightening regulatory complexities.
Many firms lack leadership versed in regulatory strategy and global approval pathways—leading to delays and attrition.

1.3 Capital & investment constraints

Europe trails behind the U.S. in scale-up funding: healthtech attracted €6.4 bn in 2023, but biotech trails due to lower R\&D and VC investment.
Risk-averse leadership culture and slow commercialization further exacerbate underinvestment .

1.4 Sustainability, equity, access

Medtech products often remain inaccessible or unaffordable in low- and middle-income markets: e.g. only \~35% of global COVID tests reached those regions by 2023.
Limited focus on Health Equity in leadership—many strategies remain superficial due to lack of dedicated execution .

2. Leadership Skills for the Next Generation

2.1 Strategic & Adaptive Thinking

Leaders must navigate ambiguity—balancing innovation, compliance, and digital change amid uncertainty .
Skills needed: strategic foresight, regulatory agility, and ecosystem-driven thinking.

2.2 3‑D fluency: Data • Digital • Design

McKinsey emphasizes that leaders need “3‑D savviness”—data, design thinking, and digital capabilities.
In biotech, this includes AI/ML‑driven drug discovery, big‑data competencies, and digital supply chain oversight; in medtech—digital health, device‑data platforms

2.3 People management & culture building

Must lead cross-functional, multicultural teams, prioritize mentoring, DEI (Diversity, Equity, Inclusion), and culture shift.
Emotional intelligence, storytelling, and stakeholder management are key.

2.4 Entrepreneurial & execution excellence

Bridging science and commercialization demands agile, entrepreneurial leadership—capable of scaling operations, fundraising, and navigating clinical/regulatory journeys.

2.5 Equity- and sustainability-driven leadership**

Future leaders must embed health equity, cost-effectiveness, and sustainability into product design and markets.
This means building robust business cases that showcase long-term societal and economic returns.

3. Gaps Undermining Sustainable Health Innovation

One of the key obstacles to transforming biotech and medtech into engines of sustainable medicine is the set of persistent leadership and structural gaps:

Leadership & strategy: Weak leadership hampers the ability to scale innovations effectively. This results in higher operational costs and delays in delivering care to patients who need it most.
Digital and regulatory expertise: A lack of fluency in digital technologies and regulatory frameworks slows down the adoption of AI-driven R&D, delays medical device approvals, and increases compliance costs, ultimately restricting market access.
Funding and risk appetite: Many organizations operate within conservative cultures that resist high-risk, high-reward innovation. This stifles funding flows and stalls the growth of promising biotech and medtech pipelines.
Equity awareness: When equity is not embedded in leadership priorities, outcomes include inflated pricing models, limited coverage in underserved populations, and missed opportunities to scale innovations globally.

—

4. Recommendations: What Next-Gen Leaders Need

1. Robust leadership training platforms

Europe needs blended programs that train strategy, regulation, digital, equity, and people leadership (e.g. EIT Health WorkInHealth model).

2. Regulatory–commercial fusion roles

Break siloes—embed Regulatory Strategists and Digital Officers early, not as afterthoughts.

3. Open Innovation & Ecosystem Leadership

Foster partnerships with academia, corporates, start‑ups, payers, and regulators to drive scale and diffusion across markets .

4. Value-based & equity Leadership

Build full-cost, health-outcome business cases—not just short-term ROI—to justify sustainable and equitable deployment .

5. Funding–talent pipelines

Encourage VC, corporates, universities, and government to invest in early-career leadership focused on biotech, medtech, digital, and scale-up execution.

5. European Outlook & Global Relevance

Europe hosts 3,000+ healthtech start-ups, strong ecosystems (Medicon Valley, Golden Triangle), and leading biotech/medtech patent activity (42% globally).
Yet EU’s share of global R\&D has dropped (\~25% → <20%), hindered by fragmented markets, funding shortfalls, and regulatory drag .
Moving forward, Europe must upskill its leadership across digital, strategic, regulatory, and equity dimensions to reclaim global scale.

Final Take

To deliver **sustainable medicine** that drives **positive health outcomes at reasonable cost**, biotech & medtech must invest heavily in **leadership transformation**. It’s not enough to innovate technologically: Europe and global players need leaders equally fluent in strategy, digital, regulatory, finance, people, and equity. Only then can we turn scientific potential into accessible and affordable care for all.

References & Further Reading:

Data sources: EIT Health, Heidrick & Struggles, BCG, Syenza, McKinsey, European Parliament.